Torin 1
Torin 1 (CAS 1222998-36-8) is a potent, selective ATP-competitive inhibitor targeting mammalian target of rapamycin (mTOR) kinase, effectively inhibiting both mTOR-containing complexes, mTORC1 and mTORC2, with reported IC50 values of 2 nM and 10 nM, respectively. mTOR functions as a catalytic subunit in these multifunctional complexes, which regulate fundamental processes of cellular growth, proliferation, and survival. By strongly inhibiting both complexes, particularly mTORC1, Torin 1 suppresses rapamycin-resistant downstream signaling and attenuates cellular proliferation. It serves as a valuable tool in biomedical research exploring mTOR signaling pathways, oncology, and related cellular processes.
References:
[1]Thoreen CC1, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009 Mar 20;284(12):8023-32. doi: 10.1074/jbc.M900301200. Epub 2009 Jan 15.
[2]Liu Q1, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53(19):7146-55. doi: 10.1021/jm101144f.
- 1. Jeffrey J. Kelu, Simon M. Hughes, et al. "Muscle peripheral circadian clock drives nocturnal protein degradation via raised Ror/Rev-erb balance and prevents premature sarcopenia." Proc Natl Acad Sci U S A. 2025 May 13;122(19):e2422446122. PMID: 40324095
- 2. Rui Guo, Yanhui Li, et al. "Saturated Phosphatidic Acids Induce mTORC1-Driven Integrated Stress Response Contributing to Glucolipotoxicity in Hepatocytes." Am J Physiol Gastrointest Liver Physiol. 2025 Jun 1;328(6):G663-G676. PMID: 40241617
- 3. Wenyue Yang, Zhou Zhu, et al. "The rheumatoid arthritis drug Auranofin targets peroxiredoxin 1 and peroxiredoxin 2 to trigger ROS-endoplasmic reticulum stress axis-mediated cell death and cytoprotective autophagy." Free Radic Biol Med. 2025 Jun:233:1-12 PMID: 40089079
- 4. Anna K Breen, Sarah Thomas, et al. "An mTOR Inhibitor Discovery System Using Drug-Sensitized Yeast." Geroscience. 2025 Jan 30. PMID: 39885115
- 5. Rui Guo, Yanhui Li, et al. "Increasing cellular NAD+ protects hepatocytes against palmitate-induced lipotoxicity by preventing PARP-1 inhibition and the mTORC1-p300 pathway activation." Am J Physiol Cell Physiol. 2025 Mar 1;328(3):C776-C790. PMID: 39871470
- 6. Chengjia You, Fangyuan Shen, et al. "O-GlcNAcylation mediates Wnt-stimulated bone formation by rewiring aerobic glycolysis." EMBO Rep. 2024 Sep 10. PMID: 39256595
- 7. Tingting Wei, Na Liu, et al. "Low-dose cadmium telluride quantum dots trigger M1 polarization in macrophages through mTOR-mediated transcription factor EB activation." NanoImpact. 2024 Apr:34:100505. PMID: 38579989
- 8. Pengchen Chen, Xiaoru Zhong, et al. "Triptolide induces apoptosis and cytoprotective autophagy by ROS accumulation via directly targeting peroxiredoxin 2 in gastric cancer cells." Cancer Lett. 2024 Apr 10:587:216622. PMID: 38246224
- 9. Lydia Daboussi, Giancarlo Costaguta, et al. "Mitf is a Schwann cell sensor of axonal integrity that drives nerve repair." Cell Rep. 2023 Nov 28;42(11):113282 PMID: 38007688
- 10. Jake W Carrasquillo Rodríguez, Onyedikachi Uche, et al. "Differential reliance of CTD-nuclear envelope phosphatase 1 on its regulatory subunit in ER lipid synthesis and storage." bioRxiv. 2023 Oct 13:2023.10.12.562096. PMID: 37873275
- 11. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022.
- 12. Jordan E Hollembeak, Michael A Model. "Stability of Intracellular Protein Concentration under Extreme Osmotic Challenge." Cells. 2021 Dec 14;10(12):3532. PMID: 34944039
- 13. Holly Merta, Jake W. Carrasquillo Rodríguez, et al. "Cell cycle regulation of ER membrane biogenesis protects against chromosome missegregation." Dev Cell. 2021 Dec 20;56(24):3364-3379.e10. PMID: 34852214
- 14. Bikash Ranjan Sahoo. "HOST CELL RESPONSES TO ZIKA VIRUS INFECTION." University of Nebraska, August, 2021.
- 15. Yilei Zhang, Robert V Swanda, et al. "mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation." Nat Commun. 2021 Mar 11;12(1):1589. PMID: 33707434
- 16. Bikash R. Sahoo, Aryamav Pattnaik, et al. "Mechanistic Target of Rapamycin (mTOR) Signaling Activation Antagonizes Autophagy to Facilitate Zika Virus Replication." J Virol 2020 Sep 2;JVI.01575-20. PMID: 32878890
- 17. Wang J, Chen Y, et al. "mTORC1-IRE1α pathway activation contributes to palmitate-elicited triglyceride secretion and cell death in hepatocytes." Exp Biol Med (Maywood). 2020;1535370220928276. PMID: 32436749
- 18. Martin-Hurtado A, Martin-Morales R, et al. "NRF2-dependent gene expression promotes ciliogenesis and Hedgehog signaling." Sci Rep. 2019 Sep 25;9(1):13896. PMID: 31554934
- 19. Zhang C, Duan Y, et al. "TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1." Clin Cancer Res. 2019 Aug 5. pii: clincanres.0733.2019. PMID: 31383732
- 20. Rodríguez-Sánchez I, Schafer XL, et al. "The Human Cytomegalovirus UL38 protein drives mTOR-independent metabolic flux reprogramming by inhibiting TSC2." PLoS Pathog. 2019 Jan 24;15(1):e1007569. PMID: 30677091
- 21. Aline Pfefferle, Benedikt Jacobs, et al. "Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity." bioRxiv. 2019 January 09. PMID: 30530705
- 22. Zhang Q, Presswalla F, et al. "A platform for assessing outer segment fate in primary human fetal RPE cultures." Exp Eye Res. 2018 Oct 15;178:212-222. PMID: 30336126
- 23. Admasu TD, Chaithanya Batchu K, et al. "Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling." Dev Cell. 2018 Oct 8;47(1):67-79.e5. PMID: 30269951
- 24. Wang K, Zhang T, et al."Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux." Autophagy.2018;14(2):269-282. PMID: 29172997
- 25. Navid Koleini, Barbara E. Nickel, et al. "Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway." Oncotarget.2017 August 24.
- 26. Jensen H, Potempa M, et al. "Cutting Edge: IL-2-Induced Expression of the Amino Acid Transporters SLC1A5 and CD98 Is a Prerequisite for NKG2D-Mediated Activation of Human NK Cells." J Immunol. 2017 Aug 7. pii: ji1700497. PMID: 28784848
| Physical Appearance | A solid |
| Storage | Desiccate at -20°C |
| M.Wt | 607.64 |
| Cas No. | 1222998-36-8 |
| Formula | C35H28F3N5O2 |
| Synonyms | Torin1;Torin-1 |
| Solubility | insoluble in DMSO; insoluble in H2O; ≥2.42 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | 1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-quinolin-3-ylbenzo[h][1,6]naphthyridin-2-one |
| SDF | Download SDF |
| Canonical SMILES | CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
MEFs |
|
Preparation method |
Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
4 days; 1-6 h |
|
Applications |
250 nM Torin1 fully inhibits cell proliferation and induces a G1/S cell cycle arrest. Furthermore, 250 nM Torin1 decreases cell size to a larger degree than 50 nM rapamycin. In addtion, Torin1 disrupts mTORC1-dependent phenotypes more Completely than rapamycin. |
| Animal experiment [2]: | |
|
Animal models |
U87-MG glioblastoma mice xenografts |
|
Dosage form |
Once daily IP dosing of 20 mg/kg |
|
Preparation method |
Dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone |
|
Applications |
Torin1 treatment for 10 consecutive days leads to a greater than 99% inhibition of tumor growth. The tumor continues to grow after halt of the treatment, indicating that Torin1 is primarily cytostatic and that a substantial number of tumor cells are still viable during treatment. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: 1. Thoreen CC, Kang SA, Chang JW et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009 Mar 20;284(12):8023-32. 2. Liu Q, Chang JW, Wang J et al. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53(19):7146-55. |
|
| Description | Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM. | |||||
| Targets | mTOR | |||||
| IC50 | 2-10 nM | |||||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
